Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective

Data Availability

Some of the efficacy data used to inform the budget impact model was sourced from the Temesgen et al. (2021) publication (attached). Additional efficacy data are not publicly available at this time.

https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1